One possibility is that pharmaceutical-mediated RAF1 inhibition is more complete, that is, residual RAF1 activity could be present upon shRNA and CRISPR-mediated RAF1 inhibition and thus support infection to a greater extent than pharmaceutical inhibition. This evidence concerns the gene RAF1 and infection.